NCT04941105View on ClinicalTrials.gov

Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions
Sars-CoV-2 Infection
Interventions
DRUG

Evolocumab

A single subcutaneous administration of 140 mg evolocumab

DRUG

Saline solution

A single subcutaneous injection of 1ml of 0,9% saline solution

Trial Locations (1)

Unknown

Antoni Jurasz University Hospital No. 1, Bydgoszcz

All Listed Sponsors
lead

Collegium Medicum w Bydgoszczy

OTHER